This map shows the geographic impact of Bleyer Wa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bleyer Wa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bleyer Wa more than expected).
This network shows the impact of papers produced by Bleyer Wa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bleyer Wa. The network helps show where Bleyer Wa may publish in the future.
Co-authorship network of co-authors of Bleyer Wa
This figure shows the co-authorship network connecting the top 25 collaborators of Bleyer Wa.
A scholar is included among the top collaborators of Bleyer Wa based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Bleyer Wa. Bleyer Wa is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
18 of 18 papers shown
1.
Ds, Alberts & Bleyer Wa. (1996). Future development of amifostine in cancer treatment.. PubMed. 23(4 Suppl 8). 90–9.19 indexed citations
2.
Wa, Bleyer. (1995). The past and future of cancer in the young.. PubMed. 17(4). 285–90.3 indexed citations
3.
Balis, Frank M., et al.. (1990). Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.. PubMed. 50(15). 4464–7.18 indexed citations
4.
Wa, Bleyer. (1989). Remaining problems in the staging and treatment of childhood lymphoblastic leukemia.. PubMed. 11(4). 371–9.7 indexed citations
5.
Wootton, P., et al.. (1988). Rodent model of chemoradiotherapy-induced white matter necrosis.. PubMed. 59–64.6 indexed citations
6.
Dr, Miller, et al.. (1985). Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.. PubMed. 69(10). 1211–21.37 indexed citations
7.
Wa, Bleyer & Poplack Dg. (1985). Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries.. PubMed. 12(2). 131–48.129 indexed citations
8.
Morgan, Elaine, Edward S. Baum, Bleyer Wa, et al.. (1984). Treatment of patients with metastatic osteogenic sarcoma: a report from the Children's Cancer Study Group.. PubMed. 68(4). 661–4.18 indexed citations
9.
Wa, Bleyer, et al.. (1984). Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells.. PubMed. 68(3). 521–5.1 indexed citations
Wa, Bleyer. (1981). Neurologic sequelae of methotrexate and ionizing radiation: a new classification.. PubMed. 65 Suppl 1. 89–98.204 indexed citations
12.
Krivit, William, et al.. (1980). Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.. PubMed. 63(11-12). 1755–9.69 indexed citations
13.
Dg, Poplack, Bleyer Wa, & Pizzo Pa. (1979). Experimental approaches to the treatment of CNS leukemia.. PubMed. 1(2). 141–9.10 indexed citations
14.
Pa, Pizzo, Poplack Dg, & Bleyer Wa. (1979). Neurotoxicities of current leukemia therapy.. PubMed. 1(2). 127–40.64 indexed citations
15.
Wa, Bleyer, et al.. (1978). Failure of moderate-dose prolonged-infusion methotrexate and citrovorum factor rescue in patients with previously treated metastatic neuroblastoma--a phase II study.. PubMed. 62(7). 1097–9.3 indexed citations
16.
Wa, Bleyer. (1977). Current status of intrathecal chemotherapy for human meningeal neoplasms.. PubMed. 46. 171–8.45 indexed citations
17.
Rl, Dedrick, et al.. (1975). Pharmacokinetic considerations on resistance to anticancer drugs.. PubMed. 59(4). 795–804.30 indexed citations
18.
Wa, Bleyer, et al.. (1975). Potential biologic markers in Burkitt's lymphoma.. PubMed. 59(4). 721–7.23 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.